{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-26-000078","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2026-09-14T12:37:42+00:00","discovered_at":"2026-09-14T12:40:01.496274+00:00","generated_at":"2026-09-14T12:40:25.014726+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Ivonescimab HARMONi-2 shows OS benefit: HR 0.73, median OS 30.8 vs 22.6 months vs pembrolizumab","bullets":["HARMONi-2 OS HR 0.73 (95% CI 0.57-0.95; p=0.009); median OS 30.8 vs 22.6 months.","PD-L1 high subgroup HR 0.58; PD-L1 low HR 0.85; squamous HR 0.65; non-squamous HR 0.79.","Serious TRAEs: 29.9% (ivonescimab) vs 21.6% (pembrolizumab); discontinuation 4.1% vs 5.0%.","Summit's global Phase III HARMONi-7 (NCT06767514) targets 780 patients with PD-L1 high-expressing NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-26-000078","json":"https://secwatch.observer/filing/0001599298-26-000078.json","markdown":"https://secwatch.observer/filing/0001599298-26-000078.md","text":"https://secwatch.observer/filing/0001599298-26-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000078/0001599298-26-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000078/smmt-20260913.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T12:40:25.014726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}